Haematopoietic stem cell transplantation for autoimmune diseases

JF Swart, EM Delemarre, F Van Wijk… - Nature Reviews …, 2017 - nature.com
Autologous haematopoietic stem cell transplantation (HSCT) is the only treatment that is
able to induce long-term, drug-free and symptom-free remission in several refractory …

Treating juvenile idiopathic arthritis to target: recommendations of an international task force

A Ravelli, A Consolaro, G Horneff, RM Laxer… - Annals of the …, 2018 - ard.bmj.com
Recent therapeutic advances in juvenile idiopathic arthritis (JIA) have made remission an
achievable goal for most patients. Reaching this target leads to improved outcomes. The …

Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis

MJH Doeleman, EM Van Maarseveen… - Rheumatology, 2019 - academic.oup.com
Objective The clinical impact of anti-drug antibodies (ADAbs) in paediatric patients with JIA
remains unknown. This systematic review and meta-analysis aimed to summarize the …

Understanding inflammation in juvenile idiopathic arthritis: How immune biomarkers guide clinical strategies in the systemic onset subtype

JF Swart, S de Roock… - European journal of …, 2016 - Wiley Online Library
The translation of basic insight in immunological mechanisms underlying inflammation into
clinical practice of inflammatory diseases is still challenging. Here we describe how …

Predictors of health‐related quality of life in children and adolescents with juvenile idiopathic arthritis: results from a web‐based survey

L Haverman, MA Grootenhuis… - Arthritis care & …, 2012 - Wiley Online Library
Objective Children with juvenile idiopathic arthritis (JIA) experience functional impairment
due to joint manifestations of the disease. The aim of our present study was to assess health …

Factors associated with treatment response to etanercept in juvenile idiopathic arthritis

MH Otten, FHM Prince, W Armbrust, R ten Cate… - Jama, 2011 - jamanetwork.com
Context Since the introduction of biologic therapies, the pharmacological treatment
approach for juvenile idiopathic arthritis (JIA) has changed substantially, with achievement …

[PDF][PDF] Treatment to target using recombinant interleukin‐1 receptor antagonist as first‐line monotherapy in new‐onset systemic juvenile idiopathic arthritis: results from …

NM Ter Haar, EHP van Dijkhuizen… - Arthritis & …, 2019 - Wiley Online Library
Objective Systemic juvenile idiopathic arthritis (JIA) is a multifactorial autoinflammatory
disease with a historically poor prognosis. With current treatment regimens, approximately …

Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis

JF Swart, EHP van Dijkhuizen, NM Wulffraat… - Annals of the …, 2018 - ard.bmj.com
Objectives To assess if the Juvenile Arthritis Disease Activity Score (JADAS71) could be
used to correctly identify patients with juvenile idiopathic arthritis (JIA) in need of antitumour …

Definition and validation of the American College of Rheumatology 2021 juvenile arthritis disease activity score cutoffs for disease activity states in juvenile idiopathic …

C Trincianti, EHP Van Dijkhuizen… - Arthritis & …, 2021 - Wiley Online Library
Objective To develop and validate new Juvenile Arthritis Disease Activity Score 10
(JADAS10) and clinical JADAS10 (cJADAS10) cutoffs to separate the states of inactive …

Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register

MH Otten, J Anink, FHM Prince, M Twilt… - Annals of the …, 2015 - ard.bmj.com
Background Treatment of juvenile idiopathic arthritis (JIA) has changed dramatically since
the introduction of biological agents in 1999. Objective To evaluate trends in prescription …